A smart drug-delivery nanosystem based on carboxylated graphene quantum dots for tumor-targeted chemotherapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
  Medline CASGoogle Scholar
• 2. Lammers T, Aime S, Hennink WE et al. Theranostic nanomedicine. Acc. Chem. Res. 44, 1029–1038 (2011).
  Medline CASGoogle Scholar
• 3. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. JCO 33, 1974–1982 (2015).
  Medline CASGoogle Scholar
• 4. Morton SW, Lee MJ, Deng ZJ et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 7, ra44 (2014).
  MedlineGoogle Scholar
• 5. Topalian SL, Taube JM, Anders RA et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
  Medline CASGoogle Scholar
• 6. Botchkarev VA, Sharov AA. Modeling chemotherapy-induced hair loss: from experimental propositions toward clinical reality. J. Invest. Dermatol. 136, 557–559 (2016).
  Medline CASGoogle Scholar
• 7. Wicki A, Witzigmann D, Balasubramanian V et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Rel. 200, 138–157 (2015).
  Medline CASGoogle Scholar
• 8. Liu J, Detrembleur C, De Pauw-Gillet MC et al. Gold nanorods coated with mesoporous silica shell as drug delivery system for remote near infrared light-activated release and potential phototherapy. Small 11, 2323–2332 (2015).
  MedlineGoogle Scholar
• 9. Cheng CJ, Bahal R, Babar IA et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107–110 (2015).
  Medline CASGoogle Scholar
• 10. Xu Z, Zhu S, Wang M et al. Delivery of paclitaxel using pegylated graphene oxide as a nanocarrier. ACS Appl. Mater. Interfaces 7, 1355–1363 (2015).
  Medline CASGoogle Scholar
• 11. Chung C, Kim YK, Shin D et al. Biomedical applications of graphene and graphene oxide. Acc. Chem. Res. 46, 2211–2224 (2013).
  Medline CASGoogle Scholar
• 12. Behzadi S, Serpooshan V, Tao W et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218–4244 (2017).
  Medline CASGoogle Scholar
• 13. Wu D, Zhang F, Liang H et al. Nanocomposites and macroscopic materials: assembly of chemically modified graphene sheets. Chem. Soc. Rev. 41, 6160–6177 (2012).
  Medline CASGoogle Scholar
• 14. Ji H, Zhang L, Pettes MT et al. Ultrathin graphite foam: a three-dimensional conductive network for battery electrodes. Nano Lett. 12, 2446–2451 (2012).
  Medline CASGoogle Scholar
• 15. Ahn G, Kim HR, Ko TY et al. Optical probing of the electronic interaction between graphene and hexagonal boron nitride. ACS Nano 7, 1533–1541 (2013).
  Medline CASGoogle Scholar
• 16. Yang K, Gong H, Shi X et al. In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 34, 2787–2795 (2013).
  Medline CASGoogle Scholar
• 17. Jaworski S, Sawosz E, Kutwin M et al. In vitro and in vivo effects of graphene oxide and reduced graphene oxide on glioblastoma. Int. J. Nanomater. 10, 1585–1596 (2015).
  Medline CASGoogle Scholar
• 18. Fan JL, Zhang XZ, Cheng YX et al. Increasing the sensitivity and selectivity of a GONS quenched probe for an mRNA assay assisted with duplex specific nuclease. RSC Adv. 7, 35629–35637 (2017).
  CASGoogle Scholar
• 19. Liu Z, Robinson JT, Sun X et al. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130, 10876–10877 (2008).
  Medline CASGoogle Scholar
• 20. Yang LC, Zhong XY, Li Q et al. Potentiation of drug induced phospholipidosis in vitro through PEGlyated graphene oxide as the nanocarrier. Toxicol. Sci. 156, 39–53 (2017).
  Medline CASGoogle Scholar
• 21. Wang Y, Polavarapu L, Liz-Marzán LM. Reduced graphene oxide-supported gold nanostars for improved SERS sensing and drug delivery. ACS Appl. Mater. Interfaces 6, 21798–21805 (2014).
  Medline CASGoogle Scholar
• 22. Miao W, Shim G, Kang CM et al. Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials 34, 9638–9647 (2013).
  Medline CASGoogle Scholar
• 23. Weaver CL, Larosa JM, Luo X et al. Electrically controlled drug delivery from graphene oxide nanocomposite films. ACS Nano 8, 1834–1843 (2014).
  Medline CASGoogle Scholar
• 24. Shim G, Kim JY, Han J et al. Reduced graphene oxide nanosheets coated with an anti-angiogenic anticancer low-molecular-weight heparin derivative for delivery of anticancer drugs. J. Control. Rel. 189, 80–89 (2014).
  Medline CASGoogle Scholar
• 25. Cheng C, Li S, Thomas A et al. Functional graphene nanomaterials based architectures: biointeractions, fabrications, and emerging biological applications. Chem. Rev. 117, 1826–1914 (2017).
  Medline CASGoogle Scholar
• 26. Iannazzo D, Pistone A, Salamò M et al. Graphene quantum dots for cancer targeted drug delivery. Int. J. Pharm. 518, 185–192 (2017).
  Medline CASGoogle Scholar
• 27. Li J, Zhang X, Jiang J et al. Systematic assessment of the toxicity and potential mechanism of graphene derivatives in vitro and in vivo. Toxicol. Sci. 167, 269–281 (2019). •• First systematic study of the toxicity and potential mechanism of graphene derivatives in vitro and in vivo, which indicated that carboxylated graphene quantum dots have excellent biological compatibility and ultra-low-toxicity.
  Medline CASGoogle Scholar
• 28. Ma Y, Shen H, Tu X et al. Assessing in vivo toxicity of graphene materials: current methods and future outlook. Nanomedicine 9, 1565–1580 (2014).
  CASGoogle Scholar
• 29. Li Y, Wan J, Zhang Z et al. Targeted soft biodegradable glycine/PEG/RGD-Modified poly (methacrylic acid) nanobubbles as intelligent theranostic vehicles for drug delivery. ACS Appl. Mater. Interfaces 9, 35604–35612 (2017).
  Medline CASGoogle Scholar
• 30. Bi C, Wang A, Chu Y et al. Intranasal delivery of Rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. Int. J. Nanomater. 11, 6547–6559 (2016).
  Medline CASGoogle Scholar
• 31. Chao X, Guo L, Zhao Y et al. PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery. J. Drug Target. 19, 161–170 (2011).
  Medline CASGoogle Scholar
• 32. Kumawat MK, Thakur M, Gurung RB et al. Graphene quantum dots for cell proliferation, nucleus imaging, and photoluminescent sensing applications. Sci. Rep. 7, 15858 (2017).
  Google Scholar
• 33. Li S, Zhou S, Li Y et al. Exceptionally high payload of the IR780 iodide on folic acid-functionalized graphene quantum dots for targeted photothermal therapy. ACS Appl. Mater. Interfaces 9, 22332–22341 (2017). • Shows a good tumor targeting of folic acid-functionalized graphene quantum dots in vivo.
  Medline CASGoogle Scholar
• 34. Ding H, Zhang F, Zhao C et al. Beyond a carrier: graphene quantum dots as a probe for programmatically monitoring anti-cancer drug delivery, release, and response. ACS Appl. Mater. Interfaces 9, 27396–27401 (2017).
  Medline CASGoogle Scholar
• 35. Chen J, Zhang W, Zhang M et al. Mn(II) mediated degradation of artemisinin based on Fe₃O₄@MnSiO₃-FA nanospheres for cancer therapy in vivo. Nanoscale 7, 12542–12551 (2015).
  Medline CASGoogle Scholar
• 36. Li H, Fu C, Miao X et al. Multifunctional magnetic co-delivery system coated with polymer mPEG-PLL-FA for nasopharyngeal cancer targeted therapy and MR imaging. J. Biomater. Appl. 31, 1169–1181 (2017).
  Medline CASGoogle Scholar
• 37. Iannazzo D, Ziccarelli I, Pistone A. Graphene quantum dots: multifunctional nanoplatforms for anticancer therapy. J. Mater. Chem. B 5, 6471–6489 (2017).
  CASGoogle Scholar
• 38. Aggarwal P, Hall JB, McLeland CB et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61, 428–437 (2009). • Comprehensively analyzes that surface modification of PEG improves biocompatibility of nanomaterials by reducing nonspecific protein adsorption in the blood, preventing flocculation and subsequent complement activation.
  Medline CASGoogle Scholar
• 39. van Dam GM, Themelis G, Crane LMA et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-[alpha] targeting: first in-human results. Nat. Med. 17, 1315–1319 (2011).
  Medline CASGoogle Scholar
• 40. Meier R, Henning TD, Boddington S et al. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology 255, 527–535 (2010).
  MedlineGoogle Scholar
• 41. Yang Y, He L, Liu Y et al. Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRα. Sci. Rep. 6, 32427 (2016).
  Google Scholar
• 42. Zheng M, Zhao P, Luo Z et al. Robust ICG theranostic nanoparticles for folate targeted cancer imaging and highly effective photothermal therapy. ACS Appl. Mater. Interfaces 6, 6709–6716 (2014).
  Medline CASGoogle Scholar
• 43. Nägele H, Castel MA, Deutsch O et al. Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy. J. Heart Lung Transplant. 23, 641–643 (2004).
  Medline CASGoogle Scholar
• 44. Safra T, Muggia F, Jeffers S et al. PEGgylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m². Ann. Oncol. 11, 1029–1033 (2000).
  Medline CASGoogle Scholar
• 45. Ramirez LH, Zhao Z, Rougier P et al. Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Cancer Chemother. Pharmacol. 37, 371–376 (1996).
  Medline CASGoogle Scholar
• 46. Chen H, Wang Z, Zong S et al. A graphene quantum dot-based FRET system for nuclear-targeted and real-time monitoring of drug delivery. Nanoscale 7, 15477–15486 (2015).
  Medline CASGoogle Scholar
• 47. Dehaini D, Wei X, Fang RH et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv. Mater. 29, 1606209 (2017).
  Google Scholar
• 48. Tian J, Luo Y, Huang L et al. PEGylated folate and peptide-decorated graphene oxide nanovehicle for in vivo targeted delivery of anticancer drugs and therapeutic self-monitoring. Biosens. Bioelectron. 80, 519–524 (2016).
  Medline CASGoogle Scholar
• 49. Chen W, Ouyang J, Liu H et al. Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer. Adv. Mater. 29, 1603864 (2017).
  Google Scholar
• 50. Ge J, Lan M, Zhou B et al. A graphene quantum dot photodynamic therapy agent with high singlet oxygen generation. Nat. Commun. 5, 4596 (2014).
  Google Scholar
• 51. Yang X, Wang Y, Huang X et al. Multi-functionalized graphene oxide based anticancer drug-carrier with dual-targeting function and pH-sensitivity. J. Mater. Chem. 21, 3448–3454 (2011).
  CASGoogle Scholar
• 52. Fu J, Zhu Y. Lysosomes activating chain reactions against cancer cells with a pH-switched prodrug/procatalyst co-delivery nanosystem. J. Mater. Chem. B 5, 996–1004 (2017).
  CASGoogle Scholar
• 53. Chen Y, Cheng L, Dong Z et al. Degradable vanadium disulfide nanostructures with unique optical and magnetic functions for cancer theranostics. Angew. Chem. Int. Ed. Engl. 56, 12991–12996 (2017).
  Medline CASGoogle Scholar
• 54. Conde J, Oliva N, Atilano M et al. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat. Mater. 15, 353–363 (2016).
  Medline CASGoogle Scholar
• 55. Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129–1132 (1997).
  Medline CASGoogle Scholar